Jaguar's Health的首席执行官将出席2025年9月的两次投资者会议,分享其植物基GI药品的最新情况。 Jaguar Health's CEO to present at two investor conferences in September 2025, sharing updates on its plant-based GI medicines.

Jaguar Health Inc. (NASDAQ:JAGX)宣布,首席执行官Lisa Conte将几乎出席2025年9月25日的新兴增长大会和2025年9月30日的Lytham伙伴2025秋季大会,分享近期商业发展的最新情况。 Jaguar Health, Inc. (NASDAQ: JAGX) announced that CEO Lisa Conte will present virtually at the Emerging Growth Conference on September 25, 2025, and the Lytham Partners Fall 2025 Conference on September 30, 2025, sharing updates on near-term business developments. 该公司的重点是用于胃肠病的植物衍生处方药、用于艾滋病毒/艾滋病患者非传染性腹泻的Mytesi市场。 The company, focused on plant-derived prescription medicines for gastrointestinal conditions, markets Mytesi® for noninfectious diarrhea in HIV/AIDS patients. 附属公司包括Napo制药公司、Napo治疗公司、Jaguar动物健康公司和Magdalena生物科学公司,这是一家开发以植物为基础的心理健康治疗的合资企业。 Subsidiaries include Napo Pharmaceuticals, Napo Therapeutics, Jaguar Animal Health, and Magdalena Biosciences, a joint venture developing plant-based mental health treatments. 演示文稿的重播将在网上提供。 Replays of the presentations will be available online. 前瞻性说明面临风险和不确定性。 Forward-looking statements are subject to risks and uncertainties.